- Home
- TCRX vs BDL Comparison
TCRX vs BDL Comparison
Compare TCRX & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | BDL |
|---|---|---|
| Founded | 2018 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.1M | 53.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCRX | BDL |
|---|---|---|
| Price | $1.02 | $31.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 717.9K | 1.9K |
| Earning Date | 11-12-2025 | 12-19-2025 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | N/A | ★ 49.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | $8,423,000.00 | ★ $206,084,000.00 |
| Revenue This Year | $286.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.93 |
| Revenue Growth | N/A | ★ 9.56 |
| 52 Week Low | $0.88 | $22.61 |
| 52 Week High | $3.21 | $35.98 |
Technical Indicators
Market Signals| Indicator | TCRX | BDL |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 47.42 |
| Support Level | $0.88 | $29.00 |
| Resistance Level | $1.10 | $31.89 |
| Average True Range (ATR) | 0.07 | 0.94 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 62.55 | 39.81 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.